Does prostaglandin D2 hold the cure to male pattern baldness?

Ashley Nieves, Luis A. Garza

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


Lipids in the skin are the most diverse in the entire human body. Their bioactivity in health and disease is underexplored. Prostaglandin D2 has recently been identified as a factor which is elevated in the bald scalp of men with androgenetic alopecia (AGA) and has the capacity to decrease hair lengthening. An enzyme which synthesizes it, prostaglandin D2 synthase (PTGDS or lipocalin-PGDS), is hormone responsive in multiple other organs. PGD2 has two known receptors, GPR44 and PTGDR. GPR44 was found to be necessary for the decrease in hair growth by PGD2. This creates an exciting opportunity to perhaps create novel treatments for AGA, which inhibit the activity of PTGDS, PGD2 or GPR44. This review discusses the current knowledge surrounding PGD2, and future steps needed to translate these findings into novel therapies for patients with AGA.

Original languageEnglish (US)
Pages (from-to)224-227
Number of pages4
JournalExperimental Dermatology
Issue number4
StatePublished - Apr 2014


  • Aging
  • Alopecia
  • Arachidonic acid
  • Baldness
  • Hair
  • Lipids
  • Prostaglandins

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Dermatology


Dive into the research topics of 'Does prostaglandin D2 hold the cure to male pattern baldness?'. Together they form a unique fingerprint.

Cite this